SGLT2 Inhibition: Uric Acid Excretion Study

NCT05210517 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Empagliflozin 25 MG
DRUG: Benzbromaron
DRUG: Empagliflozin 25 MG + benzbromarone 100 mg

Sponsor

Amsterdam UMC, location VUmc